ABOUT THIS EPISODE
Dr Nimer speaks with ecancertv at ASCO 2016 about tumour heterogeneity.
Personalised and targeted therapies have offered new insights into oncogenic pathways and limiting cell growth growth, and Dr Nimer discusses the use of neoantigens and immunotherapy to modulate the tumour microenvironment.
Categories: Medicines · Organisation of cancer · Biology · Biomarkers · Causes of cancer ·
Personalised and targeted therapies have offered new insights into oncogenic pathways and limiting cell growth growth, and Dr Nimer discusses the use of neoantigens and immunotherapy to modulate the tumour microenvironment.
Categories: Medicines · Organisation of cancer · Biology · Biomarkers · Causes of cancer ·
English
United States
TRANSCRIPT 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
SEARCH PAST EPISODES
Search past episodes of 2016 ASCO Annual Meeting.
OTHER EPISODES IN THIS PODCAST
Dr Van Den Bent presents at ASCO 2016 about the phase III trial, which showed that patients with anaplastic glioma without 1p/19q co-deletion benefit from adjuvant chemotherapy, according to early results from a European phase III trial.
Prof Schilsky talks to ecancertv at ASCO 2016 about the latest in precision medicine.
Professor Menon speaks with ecancertv at ASCO 2016 about screening strategies to detect early stage ovarian cancer.
Ovarian cancer was responsible for over 14,000 deaths in the US last year, but is often not diagnosed in stage I-III.
With regular screening, such as annual ultrasound and multimoda…
Dr Pal talks to ecancertv at ASCO 2016 about a study that looked at the uptake of BRCA genetic tests among young cancer survivors aged 50 or under. In particular, they compared black, hispanic, and non-hispanic white women.
The study found that there were large disparities, with significantly fewe…
Dr Choueiri speaks with ecancertv at ASCO 2016 about results from METEOR, a randomised phase III trial of cabozantinib for patients with advanced renal cell carcinoma (RCC), compared to everolimus.
Cabozantinib displayed a significant impact on previously treated patients, improving median overall…
Disclaimer: The podcast and artwork embedded on this page are from ecancer.org, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.
EDIT
Thank you for helping to keep the podcast database up to date.
